Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Page 1
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques.
Depoortere R, Johnston TH, Fox SH, Brotchie JM, Newman-Tancredi A. Depoortere R, et al. Among authors: brotchie jm. Parkinsonism Relat Disord. 2020 Sep;78:151-157. doi: 10.1016/j.parkreldis.2020.08.009. Epub 2020 Aug 13. Parkinsonism Relat Disord. 2020. PMID: 32846366
BACKGROUND: Long-term treatment of Parkinson's disease (PD) with l-DOPA typically leads to development of l-DOPA induced dyskinesia (LID). ...
BACKGROUND: Long-term treatment of Parkinson's disease (PD) with l-DOPA typically leads to development of l-DOPA induced dyskinesia ( …
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. Huot P, et al. Among authors: brotchie jm. Neuropharmacology. 2014 Jul;82:76-87. doi: 10.1016/j.neuropharm.2014.01.012. Epub 2014 Jan 18. Neuropharmacology. 2014. PMID: 24447715
L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease (PD), but its long-term administration is complicated by wearing-off and dyskinesia. ...
L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease (PD), but its long-term administration …
TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.
Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM. Johnston TH, et al. Among authors: brotchie jm. Neuropharmacology. 2013 Oct;73:337-47. doi: 10.1016/j.neuropharm.2013.06.005. Epub 2013 Jun 14. Neuropharmacology. 2013. PMID: 23770260
Long-term L-DOPA treatment for Parkinson's disease (PD) is limited by motor complications, particularly L-DOPA-induced dyskinesia (LID). ...
Long-term L-DOPA treatment for Parkinson's disease (PD) is limited by motor complications, particularly L-DOPA-induced dyskinesia (LI …
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. Huot P, et al. Among authors: brotchie jm. Pharmacol Rev. 2013 Jan 10;65(1):171-222. doi: 10.1124/pr.111.005678. Print 2013 Jan. Pharmacol Rev. 2013. PMID: 23319549 Review.
L-3,4-Dihydroxyphenylalanine (L-DOPA) remains the most effective symptomatic treatment of Parkinson's disease (PD). However, long-term administration of L-DOPA is marred by the emergence of abnormal involuntary movements, i.e., L-DOPA-induced dyskinesia (LID). ...
L-3,4-Dihydroxyphenylalanine (L-DOPA) remains the most effective symptomatic treatment of Parkinson's disease (PD). However, long-term …
A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.
Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E. Fox SH, et al. Among authors: brotchie j. Mov Disord. 2012 Sep 15;27(11):1373-8. doi: 10.1002/mds.25133. Epub 2012 Sep 13. Mov Disord. 2012. PMID: 22976821 Review.
Levodopa-induced dyskinesia (LID) is a major limitation of long-term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa-induced dyskinesia were discussed at a meeting organized by the Michael J. ...
Levodopa-induced dyskinesia (LID) is a major limitation of long-term management of Parkinson's disease. The roadblocks that have hind …
A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.
Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong-Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez-Ramirez J, Lee J, Fox SH, Martin-Iverson M, Nash JE, Piggott MJ, Brotchie JM. Johnston TH, et al. Among authors: brotchie jm. FASEB J. 2012 May;26(5):2154-63. doi: 10.1096/fj.11-195016. Epub 2012 Feb 17. FASEB J. 2012. PMID: 22345403
These data identify a new class of therapeutic in Parkinson's disease and highlight the potential benefits of studying illicit drugs that in themselves would never be considered safe for long-term therapy....
These data identify a new class of therapeutic in Parkinson's disease and highlight the potential benefits of studying illicit drugs that in …
Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
Huot P, Fox SH, Newman-Tancredi A, Brotchie JM. Huot P, et al. Among authors: brotchie jm. J Pharmacol Exp Ther. 2011 Oct;339(1):2-8. doi: 10.1124/jpet.111.184093. Epub 2011 Jul 22. J Pharmacol Exp Ther. 2011. PMID: 21784889 Review.
L-DOPA remains the most effective treatment for Parkinson's disease (PD). However, long-term administration of L-DOPA is compromised by complications, particularly dyskinesia. ...
L-DOPA remains the most effective treatment for Parkinson's disease (PD). However, long-term administration of L-DOPA is compromised …
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Alachkar A, Brotchie JM, Jones OT. Alachkar A, et al. Among authors: brotchie jm. J Mol Neurosci. 2012 Jan;46(1):145-52. doi: 10.1007/s12031-011-9539-x. Epub 2011 May 12. J Mol Neurosci. 2012. PMID: 21562737
In the untreated 6-OHDA-lesioned rats, alpha(2A) expression was elevated in the locus coeruleus (160 8% and 142 8% in lesioned and unlesioned sides compared to the comparable side in sham-operated rats). Following long-term (21 days, twice daily) treatment with L: -DOPA (2 …
In the untreated 6-OHDA-lesioned rats, alpha(2A) expression was elevated in the locus coeruleus (160 8% and 142 8% in lesioned and unlesione …
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. Huot P, et al. Among authors: brotchie jm. J Neurosci. 2011 May 11;31(19):7190-8. doi: 10.1523/JNEUROSCI.1171-11.2011. J Neurosci. 2011. PMID: 21562283 Free PMC article.
l-3,4-dihydroxyphenylalanine (l-DOPA) is the most effective treatment for Parkinson's disease, but long-term l-DOPA administration is marred by the emergence of motor complications, namely, dyskinesia and a shortening of antiparkinsonian benefit (wearing-OFF). 3,4-methylen …
l-3,4-dihydroxyphenylalanine (l-DOPA) is the most effective treatment for Parkinson's disease, but long-term l-DOPA administration is …
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM. Koprich JB, et al. Among authors: brotchie jm. Mov Disord. 2011 Jun;26(7):1225-33. doi: 10.1002/mds.23631. Epub 2011 Apr 4. Mov Disord. 2011. PMID: 21465551
In Parkinson's disease (PD), dyskinesia develops following long-term treatment with 3,4-dihydroxyphenylalanine (L-dopa). Given the prominent role of the opioid system in basal ganglia function, nonselective opioid receptor antagonists have been tested for antidyskinetic ef …
In Parkinson's disease (PD), dyskinesia develops following long-term treatment with 3,4-dihydroxyphenylalanine (L-dopa). Given the pr …
34 results